Annovera (Segesterone Ac/Ethin Estradiol) Patent Expiration, LOE Window & CMS Spending

Annovera (Segesterone Ac/Ethin Estradiol) by Mayne: FDA Orange Book LOE 2039-06-21, 0 AB generics, $8.0M 2024 CMS Part D & Medicaid spend, and $2,305 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorMayne
FDA Application & PathwayN209627 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2039-06-21
Orange Book Patents (*PED Extensions)9 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$8.0M
2024 Medicare Part D Spend$90K
2024 Medicaid Spend$8.0M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($2,305 intro WAC)